Botulinum toxin type A (BoNT-A) has shown to be a safe and effective treatment for children with chronic migraines. Our study was to assess the efficacy of the Onabotulinum toxin type A at different intervals after initiation of therapy. We conducted a retrospective and prospective analysis of 34 patients at a children's hospital where children received four rounds of the BoNT-A therapy for the treatment of chronic migraine. Among the 34 patients, 25 patients (age range: 13–21 years), who responded to the BoNT-A therapy, were included in the analysis. Patients received standard 31 injection, 155 unit's protocol. Patients were assessed every 3 months after their initial injection. Reasons for discontinuation of therapy were analyzed. After the first two BoNT-A sessions, significant improvement was observed with a decrease in headache frequency and intensity (p < 0.001). There was further reduction in headache frequency and intensity with the fourth round of BoNT-A therapy, with comparative analysis between the second and fourth round showing a p-value of <0.001. In terms of reduction of emergency room visits and hospitalization, a significant improvement was seen after the third round of BoNT-A therapy (p < 0.01). A significant decrease in the number of abortive and preventive medications was seen after the second round of BoNT-A therapy (p < 0.001). The efficacy of BoNT-A treatment in decreasing headache frequency, intensity, and the number of abortive and preventive medications can be assessed effectively after two treatment sessions. This trend continued to be observed with additional third and fourth sessions.

A 型肉毒杆菌毒素 (BoNT-A) 已被证明是治疗慢性偏头痛儿童的安全有效的方法。我们的研究是在开始治疗后的不同时间间隔评估 A 型肉毒杆菌毒素的疗效。我们对一家儿童医院的 34 名患者进行了回顾性和前瞻性分析，儿童接受了四轮 BoNT-A 治疗慢性偏头痛。在 34 名患者中，对 BoNT-A 治疗有反应的 25 名患者（年龄范围：13-21 岁）被纳入分析。患者接受标准的 31 次注射，155 单位的方案。患者在初次注射后每 3 个月进行一次评估。分析停止治疗的原因。在前两次 BoNT-A 会议之后，p  < 0.001)。第四轮 BoNT-A 治疗的头痛频率和强度进一步降低，第二轮和第四轮之间的比较分析显示p值 <0.001。在减少急诊就诊和住院治疗方面，第三轮 BoNT-A 治疗后出现显着改善（p  < 0.01）。在第二轮 BoNT-A 治疗后，流产和预防药物的数量显着减少（p < 0.001)。在两次治疗后，可以有效地评估 BoNT-A 治疗在降低头痛频率、强度以及无效和预防药物数量方面的功效。这种趋势在第三次和第四次会议上继续观察到。